When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, “Journavx has been placed on Tier 3 of the Optum ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $525.00. The company’s shares closed yesterday at $486.22.

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

The structure cost for the four PV modules was $29,936, $30,663, $33,936 and $30,542, with Trinasolar’s Vertex S+ 500W+ modules remaining the lowest among the four. Trinasolar’s Vertex S+ 500W ...

Journavx costs $15.50 per 50 mg tablet, taken twice daily, making it pricier than opioids. Vertex's Q4 sales hit $2.91 billion, up 16% YoY, beating the $2.78 billion consensus. Find out which ...

DA Davidson has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Vertex’s current full-year earnings is $0.38 per share. Get Vertex alerts: Vertex (NASDAQ ...

Vertex has stepped up its interest in kidney disease over the past year, moving inaxaplin into a phase 2/3 AMKD trial at the start of April and inking a $4.9 billion deal to buy Alpine Immune ...

There are plenty of crafty details in Apple TV's hit series, Severance, but if you're a design fan that mysterious Lumon logo may have caught your eye. On the surface, it's the perfect unassuming ...

Claude 3.7 Sonnet is available starting Monday in the Claude app and for developers through Anthropic’s API, Amazon Bedrock, and Google Cloud’s Vertex AI ... shouldn’t take long to answer ...

Vertex Pharmaceuticals recently obtained ... (based on analyst expectations), which isn't a terribly high multiple given the company's promising growth potential. Year to date, shares of Vertex ...